In vitro evaluation of fotemustine as a potential agent for limb perfusion in melanoma

Melanoma Research

Volumn 8, Issue 1, 1998, Pages 67-75

  Hayes, M T ^a,b   Bartley, J ^b   Parsons, P G ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Adenovirus; Cell cycle; Fotemustine; Melanoma; Methyl transferase; Resistance

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; ALKYLATING AGENT; CHLOROETHYLNITROSOUREA; DACARBAZINE; FOTEMUSTINE; MELPHALAN; N METHYL N(1) NITRO N NITROSOGUANIDINE; NITROSOGUANIDINE; UNCLASSIFIED DRUG;

ALKYLATION; ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTHERMIA; LIMB PERFUSION; MELANOMA; PRIORITY JOURNAL; PROTEIN CROSS LINKING;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS; CARCINOGENS; CELL CYCLE; CELL SURVIVAL; DNA, NEOPLASM; DRUG EVALUATION; HUMANS; HYPERTHERMIA, INDUCED; MELANOMA; METHYLNITRONITROSOGUANIDINE; NITROSOUREA COMPOUNDS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; ORGANOPHOSPHORUS COMPOUNDS; PERFUSION; SKIN NEOPLASMS; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 0031917959     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199802000-00012     Document Type: Article

References (41)

1. Coates AS. Systemic chemotherapy for malignant melanoma. World J Surg 1992; 16: 277-281.
2. Krementz ET, Carter RD, Sutherland CM, et al. Regional chemotherapy for melanoma. A 35-year experience. Ann Surg 1994; 220: 520-534.
3. Kroon BB. Regional isolation perfusion in melanoma of the limbs; accomplishments, unsolved problems, future. Eur J Surg Oncol 1988; 14: 101-110.
4. Ho VC, Sober AJ. Therapy for cutaneous melanoma: an update. J Am Acad Dermatol 1990; 22: 159-176.
5. Monson JR, Donohue JH. Long-term results of a randomized trial of hyperthermic limb perfusion (HLP) with chemotherapy for extremity melanoma. World J Surg 1990; 14: 845-846.
6. Clark J, Grabs AJ, Parsons PG, et al. Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma. Melanoma. Res 1994; 4: 365-370.
7. Schallreuter KU, Wood JM. Sensitivity and resistance in human metastatic melanoma to the new chloroethylnitrosourea anti-tumor drug fotemustine. Biochim Biophys Acta 1991; 1096: 277-283.
8. Oliver V, Aliaga A, Lopez Lopez JJ, et al. Long-term complete remissions in patients with disseminated melanoma treated by fotemustine and dacarbazine. EurJ Cancer 1993; 29: 287.
9. Lasset C, MerroucheY, Negrier S, et al. Phase II study of fotemustine as second-line treatment after failure of immunotherapy in metastatic renal cell carcinoma. Cancer Chemother Pharmacol 1993; 32: 329-331.
10. Frenay M, Giroux B, Khoury S, et al. Phase II study of fotemustine in recurrent supratentorial malignant gliomas. EurJ Cancer 1991; 27: 852-856.
11. Khayat D, Avril MF, Gerard B, et al. Fotemustine: an overview of its clinical activity in disseminated malignant melanoma. Melanoma Res 1992; 2: 147-151.
12. Merimsky O, Inbar M, Gerard B, Chaitchik S. Fotemustine - an advance in the treatment of metastatic malignant melanoma. Melanoma Res 1992; 2: 401-406.
13. Briscoe WT, Anderson SR, May HE. Base sequence specificity of three 2-chloroethylnitrosoureas. Biochem Pharmacol 1990; 40: 1201-1209.
14. Ludlum DB. Formation of cyclic adducts in nucleic acids by the haloethylnitrosoureas. IARC Sci Publ 1986; 137-146.
15. 6-(2-chloroethyl)guanine mediates the biological effects of chloroethylnitrosoureas. Environ Health Perspect 1985; 62: 119-126.
16. Tong WP, Kirk MC, Ludlum DB. Formation of the cross-link 1-(N3-deoxycytidyl),2(N1-deoxyguanosinyl) ethane in DNA treated with N,N′-bis(2-chloroethyl)-N-nitrosourea. Cancer Res 1982; 42: 3102-3105.
17. 6-alkylguanine-DNA alkyltransferase. IARC Sci Publ 1987; 30-34.
18. 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 1990; 50: 6119-6129.
19. 6-alkylguanine. FASEB J 1992; 6: 2302-2310.
20. 6-methylguanine-DNA methyltransferase in cell survival, mutagenesis and carcinogenesis. Mutation Res 1985; 145: 1-16.
21. 6-alkylguanine function. Nucleic Acids Res 1990; 18: 3961-3966.
22. 6-alkylguanine-DNA alkyltransferase becomes covalently bound to DNA containing 1,3-bis(2-chloroethyl)-1-nitrosourea-induced precursors of interstrand cross-links. Biochem Biophys Res Commun 1987; 142: 341-347.
23. Laquerriere A, Raguenez-Viotte G, Paraire M, et al. Nitrosoureas lomustine, carmustine and fotemustine induced hepatotoxic perturbations in rats: biochemical, morphological and flow cytometry studies. Eur J Cancer 1991; 27: 630-638.
24. Pauwels O, Stassi G, Kiss R. Combination of computerized morphonuclear and multivariate analyses to characterize in vitro the antineoplastic effect of alkylating agents. J Pharmacol Toxicol Methods 1995; 33: 35-45.
25. Tapiero H, Yin MB, Catalin J, et al. Cytotoxicity and DNA damaging effects of a new nitrosourea, fotemustine, diethyl-1-[3-(2-chloroethyl)-3-nitrosoureido] ethylphosphonate-S10036. Anticancer Res 1989; 9: 1617-1622.
26. Maynard K, Parsons PG. Cross-sensitivity of methylating agents, hydroxyurea, and methotrexate in human tumor cells of the Mer phenotype. Cancer Res 1986; 46: 5009-5013.
27. Schadendorf D, Worm M, Algermissen B, Kohlmus CM, Czarnetzki BM. Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity. Cancer 1994; 73: 103-108.
28. Schallreuter KU, Wood JM. New aspects in the pathophysiology of cutaneous melanoma: a review of the role of thioproteins and the effect of nitrosoureas. Melanoma Res 199 cutaneous melanoma: a review of the role of thioproteins and the effect of nitrosoureas. Melanoma Res 1992; 1: 159-167.
29. Brakenhoff JP, Commandeur JN, Wormhoudt LW, et al. Molecular mechanisms of toxic effects of fotemustine in rat hepatocytes and subcellular rat liver fractions. Carcinogenesis 1996; 17: 715-724.
30. Tranchand B, Lucas C, Biron P, et al. Phase 1 pharmacokinetics study of high dose fotemustine and its metabolite 2-chloroethanol in patients with high grade gliomas. Cancer Chemotber Pharmacol 1993; 32: 46-52.
31. Hayward IP, Parsons PG. Comparison of virus reactivation, DNA base damage, and cell cycle effects in autologous human melanoma cells resistant to methylating agents. Cancer Res 1984; 44: 55-58.
32. 6-alkylguanine-DNA alkyltransferase activity, and reactivation of methylated adeno-virus 5 and herpes simplex virus type 1 in human melanoma cell lines. Cancer Res 1989; 49: 4813-4817.
33. Chen TR. In situ detection of Mycoplasma contamination in cell culture by fluorescent Hoechst 33258 Stain. Exp Cell Res 1977; 104: 255-262.
34. Parsons PG. Treatment-time dependence of melphalan resistance and DNA crosslinking in human melanoma cells. Cancer Res 1984; 44: 2773-2778.
35. Branch P, Hampson R, Karran P. DNA mismatch binding defects, DNA damage tolerance, and mutator phenotypes in human colorectal carcinoma cell lines. Cancer Res 1995; 55: 2304-2309.
36. Branch P, Aquilina G, Bignami M, et al. Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature 1993; 362: 652-654.
37. Fety R, Lucas C, Solere P, et al. Hepatic intra-arterial infusion of fotemustine: pharmacokinetics. Cancer Chemother Pharmacol 1992; 31: 118-122.
38. Calabrasi P, Chabner A. Antineoplastic agents. In: Goodman L, Gilman AG, eds. The Pharmacological Basis of Therapeutics, New York: Macmillan, 1991, Vol 2, 1209-1223.
39. Buckley NA. A regioselective mechanism for mutagenesis and oncogenesis caused by alkylnitrosourea: a sequence specific DNA alkylation. J Am Chem Soc 1987; 109: 7918-7920.
40. Buckley NA, Brent TP. Structure activity relations of 2-chloroethyl nitrosoureas 2. Kinetic evidence for a novel mechanism for the cytotoxicity of important DNA cross-linking reactions of 2 (chloroethyl)nitrosoureas. J Am Chem Soc 1988; 110: 7520.
41. 6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells. Br J Cancer 1993; 67: 216-221.